We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$904M
AUM Growth
+$113M
Cap. Flow
+$79M
Cap. Flow %
8.74%
Top 10 Hldgs %
30.09%
Holding
103
New
13
Increased
46
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14.7M
2
ABBV icon
AbbVie
ABBV
+$12.4M
3
UNH icon
UnitedHealth
UNH
+$9.71M
4
AXSM icon
Axsome Therapeutics
AXSM
+$9.24M
5
PRCT icon
Procept Biorobotics
PRCT
+$9.13M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$13.9M
2
THC icon
Tenet Healthcare
THC
+$13.8M
3
HCA icon
HCA Healthcare
HCA
+$11.4M
4
VRNA
Verona Pharma
VRNA
+$10.1M
5
GILD icon
Gilead Sciences
GILD
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$69.5B
$42.8M 4.73%
438,000
+142,000
+48% +$14.7M
LLY icon
2
Eli Lilly
LLY
$1.02T
$40.8M 4.51%
53,420
-4,450
-8% -$3.31M
ABBV icon
3
AbbVie
ABBV
$443B
$30.2M 3.34%
130,375
+61,000
+88% +$12.4M
DHR icon
4
Danaher
DHR
$137B
$26.7M 2.95%
134,452
+13,000
+11% +$2.59M
ALHC icon
5
Alignment Healthcare
ALHC
$3.08B
$25.8M 2.86%
1,479,284
+192,000
+15% +$2.85M
ISRG icon
6
Intuitive Surgical
ISRG
$127B
$21.7M 2.4%
48,500
+4,150
+9% +$1.99M
UNH icon
7
UnitedHealth
UNH
$376B
$21.6M 2.39%
62,530
+32,100
+105% +$9.71M
AXSM icon
8
Axsome Therapeutics
AXSM
$11.2B
$21M 2.32%
172,800
+82,000
+90% +$9.24M
CVS icon
9
CVS Health
CVS
$133B
$20.9M 2.31%
277,362
-18,000
-6% -$1.23M
MCK icon
10
McKesson
MCK
$100B
$20.5M 2.27%
26,600
-1,117
-4% -$787K
REGN icon
11
Regeneron Pharmaceuticals
REGN
$78.5B
$20.3M 2.25%
36,100
+8,400
+30% +$4.75M
IONS icon
12
Ionis Pharmaceuticals
IONS
$8.6B
$20.3M 2.24%
310,000
+128,000
+70% +$6.25M
MDT icon
13
Medtronic
MDT
$109B
$19.5M 2.16%
205,000
+25,500
+14% +$2.34M
COR icon
14
Cencora
COR
$60.6B
$19.5M 2.16%
62,375
+13,000
+26% +$3.83M
EXAS
15
DELISTED
Exact Sciences
EXAS
$19M 2.11%
348,000
-2,000
-0.6% -$99.9K
INSM icon
16
Insmed
INSM
$21.4B
$19M 2.1%
131,885
-43,550
-25% -$5.34M
GKOS icon
17
Glaukos
GKOS
$9.83B
$18.8M 2.08%
230,000
-5,000
-2% -$459K
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$121B
$18.4M 2.04%
46,955
-14,500
-24% -$6.06M
PODD icon
19
Insulet
PODD
$11.5B
$17.9M 1.98%
58,000
+12,000
+26% +$3.76M
COO icon
20
Cooper Companies
COO
$14.1B
$16.2M 1.8%
237,000
+67,000
+39% +$4.75M
NBIX icon
21
Neurocrine Biosciences
NBIX
$16.8B
$16.1M 1.78%
114,717
-34,500
-23% -$4.67M
EHC icon
22
Encompass Health
EHC
$11B
$15.2M 1.68%
119,400
-17,000
-12% -$2.02M
CAH icon
23
Cardinal Health
CAH
$53.9B
$14.8M 1.63%
94,000
+39,000
+71% +$6.02M
TMO icon
24
Thermo Fisher Scientific
TMO
$213B
$14.6M 1.61%
30,040
+18,900
+170% +$8.8M
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$27.5B
$14.5M 1.61%
31,875
-19,322
-38% -$7.87M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rhenman & Partners Asset Management held 103 positions worth $904M, up 14% from $791M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management deployed $79M of net new capital in Q3 2025, opening 13 new positions and adding to 46 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 18,250 shares worth $8.37M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Tenet Healthcare, an estimated $13.8M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2025 buy was Madrigal Pharmaceuticals: 18,250 shares worth $8.37M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q3 2025, an estimated $14.7M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2025 reduction was Tenet Healthcare, cutting an estimated $13.8M.
  • Rhenman & Partners Asset Management fully exited DexCom in Q3 2025, selling an estimated $13.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $904M portfolio in Q3 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q3 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $904M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.